Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 155.20 [1]. Core Views - The company achieved a revenue of RMB 2.251 billion in 2025, representing a year-over-year increase of 22.90%, and a net profit of RMB 650 million, up 39.73% year-over-year. The fourth quarter alone saw revenue of RMB 702 million, a significant increase of 47.65% year-over-year and 45.45% quarter-over-quarter [1]. - The company is expected to benefit from the performance of new products such as CT detectors, tubes, and silicon-based OLED microdisplay backplanes, which are anticipated to drive future growth [1]. - The core components and comprehensive solutions business are gradually completing major customer onboarding and beginning bulk deliveries, contributing to steady sales growth [2]. - The silicon-based microdisplay backplane business generated revenue of RMB 55.62 million, supported by the production capacity from the Hefei factory [2]. Financial Performance - The company reported a gross margin of 51.36% and a net margin of 28.09% for 2025, reflecting improvements of 1.25 and 3.5 percentage points year-over-year, respectively [3]. - The sales, management, R&D, and financial expense ratios showed varied changes, with management expenses decreasing due to effective cost control and revenue growth [3]. - The company completed a 6-year employee stock ownership plan, which is expected to enhance employee motivation and stabilize operational goals [4]. Profit Forecast and Valuation - The profit forecast for the company has been slightly adjusted downwards due to a slight contraction in the medical equipment bidding market. The expected net profits for 2026-2028 are RMB 820 million, RMB 1.05 billion, and RMB 1.25 billion, respectively [5]. - The company is valued at a PE ratio of 40 times for 2026, with an updated target price of RMB 155.20, reflecting a 53 times PE ratio for 2025 [5].